Monday, November 18, 2013
Rumors of the IPO window's
death are greatly exaggerated. Despite a handful of postponed biotech IPOs in
the last two weeks, three money managers contacted by BioCentury say the market
is merely taking a holiday as investors - in particular generalists - look to
minimize risk before year end.
The money managers think the
new year should see more IPOs getting done. But they say investors will likely
be more selective than they were over the spring and summer.